In the public NIH/SBIR.gov award database (134,084 grant records, 33,680 unique small-business awardees), one trend stands out as a genuine leading indicator: grants tagged with the NIH Research, Condition, and Disease Categorization (RCDC) code "Orphan Drug" more than doubled from 149 awards in 2013 to 364 in 2018 — and then held above 300 every year since, through 2024. That inflection happened roughly five to seven years before rare-disease biotech became a headline IPO and M&A category, and well before venture data services would have flagged the shift.
Why SBIR data leads, not lags
The mechanism is structural, not sentimental. NIH SBIR/STTR awards are peer-reviewed on scientific merit and programmatic fit with an Institute's mission, not on a market thesis or a venture partner's conviction. A two-person lab spinout can win a Phase I award (average $172,995 across our full 1983–2024 dataset) filing a grant application 12–18 months before it would be fundable enough, or de-risked enough, to raise an institutional seed round. Roughly 49% of the companies that received a Phase I award never progress to a tracked Phase II follow-on within the same company record — consistent with SBIR's well-documented function as a high-volume, low-cost-per-shot filter across therapeutic areas, years ahead of the capital that eventually concentrates around the survivors. Phase II awards, which fund actual product/clinical development, average $656,725 and require Phase I preliminary data, so a rising Phase II count in a category is a second, lagged confirmation signal on top of the earlier Phase I bulge.
Applied to therapeutic-area targeting, this means RCDC-category award counts are effectively a public, quarterly-updated proxy for where NIH study sections and small-business scientists jointly believe the biology is ready — before that belief shows up in a Series A press release. The public award data shows NIH is the dominant SBIR funder in life sciences by a wide margin: 83,903 of 134,084 grants (62.6%), versus 19,291 for HHS sub-agencies, 13,480 for DOD, and 8,271 for NSF — so the NIH slice alone is a large, coherent sample for biotech-specific signal.
A named example
Our sbir-companies index shows Progenics Pharmaceuticals (New York) drawing 117 SBIR/STTR awards totaling roughly $68 million, with its earliest tracked award in 1990 — decades before it commercialized PSMA-targeted prostate-cancer imaging and therapeutic agents and was acquired by Lantheus Holdings in a 2019–2020 all-stock transaction.[1][2] The award trail long predates the deal that made the company a headline.
Caveats
This is not a clean crystal ball. RCDC tagging is applied by NIH staff using automated text classification and can mis-bucket abstracts; a company's earliest recorded award year reflects the earliest record in the public dataset, not necessarily its true founding-round activity; and award counts say nothing about scientific quality or eventual clinical success — SBIR is explicitly a high-volume screen, and most awardees never reach an approved product. The index also stops at 2024 and undercounts current-year awards still being entered into SBIR.gov.
Why this matters: for anyone doing early-stage therapeutic-area scouting, category-level SBIR award trends are a free, public, several-year head start on where NIH-vetted science is clustering — a signal worth cross-checking against clinical-trial registrations and patent filings before venture and IPO data catch up.